ãèµ€ãé¡ã»é ãã®ã¬ãŒã¶ãŒæ²»çââIPLã»VããŒã ã»ããã³ãã¡ã®éžã³æ¹ã
86.7%ãããã¯ãããææ°æ²»çãåããæ£è ããæºè¶³ããŸãã¯ãéåžžã«æºè¶³ããšåçããå²åã§ãïŒCho et al. 2012ïŒãããããå€ãã®æ¹ã¯ãã®æ²»çã®ååããç¥ããªããŸãŸã广ã®èãã¹ãã³ã±ã¢ã«ãéãæ³šãç¶ããŠããŸãã
é¡ãèŠããã³ã«æ°ã«ãªãé¡ã®èµ€ã¿ââããªãããéææã®ããåäžãªèãåãæ»ãããããšæã£ãŠããŸãããïŒ
- èµ€ãé¡ã»è¡ç®¡æ¡åŒµã®æ ¹æ¬çãªåå ãšå»çæ©é¢ã§ã®æ²»çã®å¿ èŠæ§
- IPLïŒå æ²»çïŒã®ã¡ã«ããºã ãšãæã广ãåŒãåºããèã¿ã€ã
- VããŒã ïŒPDLïŒãã«ã¹è²çŽ ã¬ãŒã¶ãŒïŒãæ¡åŒµããè¡ç®¡ã«ãã€ã¬ã¯ãã«å¹ãçç±
- ããã³ãã¡ã«ä»£è¡šãããMNRFïŒãã€ã¯ãããŒãã«RFïŒã®ææ°æè¡ãšæè¡ç®¡æ°ç广
- åæ²»çæ³ã®ãªã¢ã«ãªå¯äœçšçºççãšããŠã³ã¿ã€ã ã®æ¯èŒããŒã¿
ã¡ã€ã¯ã§é ããããªãèµ€ã¿ããæ°æž©ã®å€åã§æ¥ã«ç®ç«ã€è¡ç®¡æ¡åŒµãããŸããŸãªã¹ãã³ã±ã¢ã詊ããŠã广ã宿ã§ãããã€ãã«ã¬ãŒã¶ãŒæ²»çãæ€èšããŠããæ¹ãå€ãã¯ãã§ãã
ããããã¯ãªããã¯ã®ããŒã ããŒãžãèŠããšãIPLãVããŒã ãããã³ãã¡ãªã©ãéžæè¢ãå€ãããŠãçµå±ã©ããèªåã«åã£ãŠããã®ãããšè¿·ã£ãŠããŸããŸãããã
å®ã¯ããã®ãã©ããèªåã«åããããšããåãã«ã¯ãèã¿ã€ããšçç¶ã®çµã¿åããã«ãã£ãŠæç¢ºãªçãããããŸããææ°ã®ã©ã³ãã 忝èŒè©Šéšãäžçäžã®ç ç©¶ããŒã¿ãéããã¡ã¿ã¢ããªã·ã¹ãæããã«ããé©ãã®äºå®ãããããªãã«æé©ãªæ²»çæ³ãèŠã€ããæå©ããããŸãã
é·å¹ŽããŠã³ã¿ã€ã ãçã¿ã«èŠããã§ããæ¹ãžã®æå ±ãšããŠãå®ã¯åŸæ¥ã®ã¬ãŒã¶ãŒããããªã¹ã¯ãäœããããããªãææ°æè¡ã«ã€ããŠã詳ãã解説ããŠãããŸãã®ã§ããã²æåŸãŸã§ãèªã¿ãã ããã
èµ€ãé¡ã»çŽ æã®ã¡ã«ããºã ãšæ²»çã®å¿ èŠæ§
è¡ç®¡ã®æ¡åŒµãšççãåŒãèµ·ããèµ€ã¿ã®æ£äœ
ããªãã¹ãã³ã±ã¢ã ãã§ã¯èµ€ã¿ãæ¶ããªãã®ãïŒãââãã®çãã¯ãç®èã®æ·±éšã§èµ·ããŠããå€åã«ãããŸãã
é¡ã®èµ€ã¿ãççåŸçŽ æïŒErythemaïŒã¯ãåãªãç®èã®è¡šé¢çãªåé¡ã§ã¯ãªããç®èã®æ·±éšã«ãããè€éãªè¡ç®¡ã®å€åãççåå¿ãé¢ä¿ããŠããŸããå»åŠçãªç ç©¶ã«ãããŠãèµ€ãé¡ãè²çŽ æ§çŸæ£ã®èæ¯ã«ã¯ãç®èã®è¡ç®¡ååžã®å¢å ããè¡ç®¡å ç®å¢æ®å åïŒVEGFïŒãšåŒã°ããã¿ã³ãã¯è³ªã®ã¬ãã«ã®äžæãæ·±ãé¢äžããŠããããšã瀺ãããŠããŸãïŒIranmanesh et al. 2021ïŒããã®VEGFãå¢å ããããšã§ãç®èã®äžã§æ°ããè¡ç®¡ãéå°ã«äœãããããæ¢åã®è¡ç®¡ãæ¡åŒµãããããŠãçµæãšããŠç®èã®è¡šé¢ããèµ€ãè²ãšããŠéããŠèŠããããã«ãªããŸãã
ããã§éèŠãªã®ã¯ããã®ãéå°ãªè¡ç®¡ããšããåé¡ã§ãã
ããããªã©ã®ççãèœã¡çããåŸã«æ®ãèµ€ãè·¡ãããããççåŸçŽ æããå€ãã®äººãæ©ãŸããçç¶ã®äžã€ã§ãããããã«é¢é£ããççåŸçŽ æã¯ãç®èã®ä¿®åŸ©éçšã§å±æçãªè¡æµãå¢å ããæ¯çŽ°è¡ç®¡ãæ¡åŒµãç¶ããããšã«ãã£ãŠåŒãèµ·ããããŸãïŒMin et al. 2016ïŒããããã®æ¡åŒµããç®èè¡ç®¡ïŒdilated skin vesselsïŒãéå°ãªè¡ç®¡ååžã¯ãæ¥åžžçãªã¹ãã³ã±ã¢ãåç²§åã ãã§æ ¹æ¬çã«è§£æ±ºããããšã¯éåžžã«å°é£ã§ãã
ã ãããããç¹å®ã®æ³¢é·ã®å ãç±ãšãã«ã®ãŒãçšããŠãç°åžžãªè¡ç®¡ãççãã®ãã®ã«çŽæ¥ã¢ãããŒãããå»çæ©é¢ã§ã®ããã€ã¹æ²»çïŒãšãã«ã®ãŒããŒã¹ã®æ²»çïŒãå¿ èŠäžå¯æ¬ ãšãªããŸãïŒIranmanesh et al. 2021ïŒã
ã§ã¯ãå ·äœçã«ã©ã®æ²»çããã©ããªèµ€ã¿ã«å¹ãã®ã§ããããã3ã€ã®æ²»çæ³ãé çªã«èŠãŠãããŸãããã
IPLïŒIntense Pulsed LightïŒïŒåºç¯å²ã®å ã§èå šäœã«ã¢ãããŒã
IPLã®ã¡ã«ããºã ãšç¹åŸŽ
ãŸãç¥ã£ãŠããã¹ãéèŠãªäºå®ããããŸããIPLã¯å³å¯ã«ã¯ãã¬ãŒã¶ãŒãã§ã¯ãããŸããã
IPLïŒIntense Pulsed LightïŒã¯ãåºç¯å²ã®æ³¢é·ãæã€éã³ããŒã¬ã³ãå ïŒæ£ä¹±å ïŒãç §å°ããããã€ã¹ã§ããIPLã®æ³¢é·ã¯éåžž500ã1200 nmã®ç¯å²ã«åã³ããã®å¹ åºãå ã®åž¯åãå©çšããããšã§ãç®èã®è¡ç®¡æåïŒãã¢ã°ããã³ïŒãšè²çŽ æåïŒã¡ã©ãã³ïŒã®äž¡æ¹ã«åæã«ã¿ãŒã²ãããçµãããšãå¯èœã§ãïŒIranmanesh et al. 2021ïŒãããã«ãããé¡ã®èµ€ã¿ã ãã§ãªããåæã«ååšããã·ãããã°ãããèã®ããã¿ãªã©ãè€æ°ã®èãã©ãã«ã«å æ¬çã«ã¢ãããŒãã§ãããšããã¡ãªããããããŸãã
ã€ãŸããã1å°ã§ããããæ¹åãããããšããæ¹åãã®ãããã°ããªãŒã«ã©ãŠã³ããŒãã§ãããã ããç¹å®ã®æ³¢é·ã®ã¿ã匷åã«ç §å°ããåäžæ³¢é·ã®ã¬ãŒã¶ãŒãšæ¯èŒãããšããã®å¹æã¯æ¯èŒçç©ããïŒmodest efficacyïŒã§ãããšè©äŸ¡ãããŠããŸãïŒIranmanesh et al. 2021ïŒã
IPLæ²»çã«é©ããèè³ªãšæ³šæç¹
ããããã誰ã§ãIPLãåããã°ããããšããããã§ã¯ãããŸãããããã倧åãªç¹ã§ãã
èšåºããŒã¿ã«ãããšãIPLã¯äž»ã«ããã£ãããããªãã¯ã®ã¹ãã³ã¿ã€ãIãIIIããšåŒã°ãããæ¯èŒçæããèïŒè²çœã®èïŒãæã€æ£è ã«æãé©ããŠããŸãïŒIranmanesh et al. 2021ïŒãããã¯ãIPLã®å ã衚ç®ã®ã¡ã©ãã³è²çŽ ã«ã匷ãåžåããããããå ã èã®è²ãæ¿ãæ¹ïŒã¹ãã³ã¿ã€ãIV以äžïŒã«ç §å°ãããšãã¿ãŒã²ããã§ããè¡ç®¡ã«å ãå±ãåã«è¡šç®ã§éå°ãªç±ãçºçããç«å·ãççåŸè²çŽ æ²çïŒPIHïŒãåŒãèµ·ãããªã¹ã¯ãé«ãŸãããã§ãã
ãŸããèµ€ãé¡ãè¡ç®¡æ¡åŒµã«å¯ŸããŠIPLãåç¬ã§äœ¿çšããå Žåãçç¶ã®æ¹åã«ã¯éçãããããšã瀺åãããŠããŸãããã®ããã飿²»æ§ã®çŽ æãè²çŽ æ§çŸæ£ãå䜵ããŠããã±ãŒã¹ã§ã¯ãIPLåç¬ã§ã¯ãªããä»ã®ã¬ãŒã¶ãŒããšãã«ã®ãŒããã€ã¹ãšã®äœµçšçæ³ããããã¯é©åãªå€çšè¬ãšã®çµã¿åãããæšå¥šãããããšãå€ããªã£ãŠããŸãïŒIranmanesh et al. 2021ïŒãIPLã¯ãé¡å šäœã®ããŒã³ã¢ããããã€ã«ããªèµ€ã¿æ¹åããåžæããè²çœã®æ¹ã«ãšã£ãŠãããŠã³ã¿ã€ã ãå°ãªãåãçµã¿ããã第äžéžæã®æ²»çãšèšããŸãã
ã§ã¯ããã£ãšåŒ·åã«è¡ç®¡ãçãæã¡ã«ãããå Žåã¯ïŒââæ¬¡ã®æ²»çæ³ãç»å ŽããŸãã
VããŒã ïŒPDLïŒãã«ã¹è²çŽ ã¬ãŒã¶ãŒïŒïŒæ¡åŒµããè¡ç®¡ãžã®ç¹ååæ²»ç
PDLïŒãã«ã¹è²çŽ ã¬ãŒã¶ãŒïŒã®æ³¢é·ãšå§åçãªè¡ç®¡éžææ§
595 nmããã®æ°åããVããŒã ãç¹å¥ã«ããŠããçç±ã®ãã¹ãŠã§ãã
VããŒã ãªã©ã®åç§°ã§ç¥ãããPDLïŒPulsed Dye LaserïŒãã«ã¹è²çŽ ã¬ãŒã¶ãŒïŒã¯ãèµ€ãé¡ãè¡ç®¡æ¡åŒµã®æ²»çã«ãããŠæã匷åãã€ç¹ç°çãªå¹æãçºæ®ããã¬ãŒã¶ãŒã®äžã€ã§ãããã®595 nmã®æ³¢é·ã¯ãè¡æ¶²äžã®é žåãã¢ã°ããã³ã«å¯Ÿããåžåçãæ¥µããŠé«ããåšå²ã®æ£åžžãªç®èçµç¹ã«ãã¡ãŒãžãäžããããšãªããç°åžžã«æ¡åŒµããæ¯çŽ°è¡ç®¡ã ããéžæçã«ç±ç Žå£ããããšãå¯èœã§ãïŒIranmanesh et al. 2021ïŒã
ã€ã¡ãŒãžãšããŠã¯ãèµ€ãè¡ç®¡ã ããçã£ããã³ãã€ã³ãçæã§ããåšå²ã®æ£åžžãªç®èã¯å®ããªãããåé¡ã®è¡ç®¡ã ããæœ°ãââãããVããŒã ã®å§åçãªåŒ·ã¿ã§ãã
ç ç©¶ã«ãããŠãPDLã¯ç¹ã«ãæ¡åŒµããç®èè¡ç®¡ïŒdilated skin vesselsïŒããæç¢ºã«ååšããèµ€ã¿ãåŒ·ãæ£è ã«å¯ŸããŠéåžžã«å¹æçã§ãããåŒ·ãæšå¥šãããæ²»çæ³ãšãããŠããŸãïŒIranmanesh et al. 2021ïŒãåè¿°ããããã«ãèµ€ãé¡ã®éšäœã§ã¯è¡ç®¡å ç®å¢æ®å åïŒVEGFïŒã®ã¬ãã«ãé«ããè¡ç®¡ã®éå°ãªåœ¢æãèŠãããŸãããPDLã¯ãã®éå°ãªè¡ç®¡ç¶²ãçŽæ¥çã«ã¿ãŒã²ããã«ããŠç Žå£ãããããæ ¹æ¬çãªèµ€ã¿ã®é€å»ã«ã€ãªãããŸãïŒIranmanesh et al. 2021ïŒã
广ãåŒãåºãããã®å ·äœçãªèšå®ãšå¯äœçšãªã¹ã¯
ãã ãã匷åãªåã ããç¥ã£ãŠããã¹ãããšããããŸãã
å®éã®èšåºè©Šéšã§äœ¿çšãããPDLã®èšå®ããŒã¿ãèŠããšãæ³¢é·595 nmã®ã¬ãŒã¶ãŒã«å¯Ÿãããšãã«ã®ãŒå¯åºŠïŒãã«ãšã³ã¹ïŒã¯7.5ã8.5 J/cm²ããã«ã¹å¹ ã¯10ã20 msãã¹ããããµã€ãºã¯10 mmãšãããã©ã¡ãŒã¿ãæ¡çšãããŠãããç®è衚é¢ãä¿è·ããããã®å·åŽè£ 眮ïŒCoolingïŒã䜵çšããªããæ²»çãè¡ãããŠããŸãïŒIranmanesh et al. 2021ïŒããã®ãããªçްããªèšå®ã«ããã广ãæå€§åãã€ã€è¡šç®ãžã®ç±ãã¡ãŒãžãæãã工倫ããªãããŠããŸãã
ããããPDLã¯è¡ç®¡ãã¿ãŒã²ããã«ãããã®åŒ·åãªæ§è³ªäžãæ²»çåŸã«ç¹æã®å¯äœçšãçããããšããããŸãã代衚çãªãã®ã玫æïŒPurpuraïŒãšåŒã°ããå åºè¡ã®ãããªã¢ã¶ã§ããæè¿ã®ç ç©¶ã§ã¯ã玫æã«ç¶ããŠççåŸè²çŽ æ²çïŒPIHïŒãçºçããå²åã5.85%ã§ãã£ããšå ±åãããŠããŸãïŒIranmanesh et al. 2021ïŒããŸãã匷ãåºåã§ç §å°ããå Žåãèµ€ã¿ïŒçŽ æïŒãè «ãïŒæµ®è «ïŒãæ°æ¥éç¶ãããŠã³ã¿ã€ã ã䌎ããããæ²»çãåããã¿ã€ãã³ã°ã«ã¯æ³šæãå¿ èŠã§ãã
VããŒã ïŒPDLïŒã¯ãå€å°ã®ããŠã³ã¿ã€ã ã蚱容ããŠã§ããæç¢ºãªè¡ç®¡æ¡åŒµãé åºãªèµ€ã¿ã確å®ã«æ²»çãããããšããæ¹ã«ãšã£ãŠãéåžžã«åŒ·åãªæŠåšãšãªããŸãã
ã§ã¯ããããŠã³ã¿ã€ã ãªãã«ããããã©ããªèã¿ã€ãã§ãå®å šã«ããšããé«ãèŠæ±ã«å¿ããæ²»çã¯ååšããã®ãââçãã¯ãYESãã§ãã
ããã³ãã¡ã«ä»£è¡šãããMNRFïŒãã€ã¯ãããŒãã«RFïŒïŒç±ãšæè¡ç®¡æ°çã®çžä¹å¹æ
MNRFïŒãã©ã¯ã·ã§ãã«ã»ãã€ã¯ãããŒãã«RFïŒã®é©æ°çãªã¡ã«ããºã
åŸæ¥ã®ã¬ãŒã¶ãŒã®åŒ±ç¹ã¯1ã€ã§ããããå ã衚ç®ãééããªããã°ãªããªãããšããå¶çŽã§ãã
MNRFã¯ãã®å¶çŽãæ ¹æ¬ããèŠããŸããã
è¿å¹ŽãçŸå®¹å»çã®äžçã§æ¥éã«æ³šç®ãéããŠããã®ããããã³ãã¡ãªã©ã®åç§°ã§ç¥ãããMNRFïŒMicroneedling RadiofrequencyïŒããŸãã¯FMRïŒFractional Microneedling RadiofrequencyïŒãšåŒã°ããæè¡ã§ããããã¯ã埮现ãªéïŒãã€ã¯ãããŒãã«ïŒãç®èã«ç©ççã«åºã蟌ã¿ããã®éã®å 端ããçç®å ã«çŽæ¥é«åšæ³¢ïŒRFïŒã©ãžãªæ³¢ïŒé»æµãæµããšããç»æçãªã·ã¹ãã ã§ãïŒCohen and Elbuluk 2016ïŒã
ã¬ãŒã¶ãŒïŒå ãšãã«ã®ãŒïŒã¯ç®èã®è¡šé¢ãã奥ãžãšé²ãéçšã§ã¡ã©ãã³ãæ°Žåã«åžåãããŠãšãã«ã®ãŒãæžè¡°ããŸãããMNRFã¯éã䜿ã£ãŠçŽæ¥ã¿ãŒã²ããå±€ïŒçç®ïŒã«ãšãã«ã®ãŒãå±ããããã衚ç®ãžã®ç¡é§ãªç±ãã¡ãŒãžã極éãŸã§æããããšãã§ããŸãã
ãããŠãããäžã€ã®é©ãã¹ãç¹ããããŸããMNRFã¯é»æµã«å¯Ÿããçµç¹ã®ã€ã³ããŒãã³ã¹ïŒæµæïŒãå©çšããŠç±ãçºçãããŸãããã®ç±ãšãã«ã®ãŒããèµ€ãé¡ã®åå ãšãªãè¡ç®¡æ¡åŒµïŒvasodilatationïŒãæå¶ããããã«ã¯æè¡ç®¡æ°ç广ïŒantiangiogenic effectsïŒãããããããšãç ç©¶ã§ç€ºãããŠããŸãïŒIranmanesh et al. 2021ïŒãã€ãŸããä»ããæ¡åŒµããè¡ç®¡ãåŒãç· ããã ãã§ãªããæ°ããªç°åžžè¡ç®¡ãäœãããã®ãé²ãåããããã®ã§ãã
èšåºããŒã¿ã瀺ãèµ€ãé¡ã»ãããè·¡ã»æ¯ç©Žãžã®é©ç°çãªå¹æ
73.3%ã70%ããããŠ58.7%ããã®3ã€ã®æ°åãäœãæå³ãããããŸãèããŠãã ããã
MNRFã¯ãèµ€ãé¡ïŒçŽ æïŒã ãã§ãªãããããè·¡ãæ¯ç©Žã®éãã«ãåæã«åªãã广ãçºæ®ããããšããå³å¯ãªã©ã³ãã 忝èŒè©Šéšã§èšŒæãããŠããŸããéåœã§è¡ãããèšåºè©ŠéšïŒCho et al. 2012ïŒã§ã¯ã30äººã®æ£è ïŒç·æ§12åã女æ§18åã幎霢16ã45æ³ïŒã察象ã«ãæ·±ã1.5mmã«èšå®ããFRMïŒFractional Radiofrequency MicroneedleïŒããã€ã¹ãçšããŠé¡å šäœã®æ²»çãè¡ããŸããããã®çµæãããã2åã®æ²»çã»ãã·ã§ã³ãã8é±éåŸã«ã¯ã73.3%ã®æ£è ã§ãããè·¡ã®ã°ã¬ãŒããæ¹åãã70%ã®æ£è ã§æ¯ç©Žã®éå€§ãæ¹åããããšã確èªãããŸããïŒCho et al. 2012ïŒã
ããã«ãã®ç ç©¶ã§ã¯ã客芳çãªè©äŸ¡ãšããŠå ±çŠç¹é¡åŸ®é¡ãçšããç»åè§£æãè¡ãããæ²»çåŸã«é¡ã®æ¯ç©Žã®é¢ç©ã58.7%ãæžå°ããããšãçµ±èšçã«ææïŒp < .001ïŒã«ç€ºãããŸããïŒCho et al. 2012ïŒããŸãå¥ã®ç ç©¶ïŒMin et al. 2015ïŒã§ã¯ãé¡ã®ååãã€ãFMRãšåŸæ¥ã®ãã€ããŒã©RFã§æ²»çãæ¯èŒããçµæãFMRã¯ççæ§ã®ãããç å€ã80%ãéççæ§ç å€ã65%ãæžå°ããããããã«é¢é£ããççåŸçŽ æïŒpost-inflammatory erythemaïŒã«å¯ŸããŠãéåžžã«æå¹ã§ããããšã瀺ãããŸããïŒMin et al. 2016ïŒãMNRFã¯ãTGF-beta1ã®å¢å ãéããŠã³ã©ãŒã²ã³ã®çæãèªå°ããçç®ã®æ§é ãã®ãã®ãåæ§ç¯ïŒãªã¢ããªã³ã°ïŒããããšã§ãèµ€ã¿ãå¹åžãæ¯ç©Žãšããè€åçãªæ©ã¿ãäžç¶²æå°œã«ã§ããæ²»çæ³ãªã®ã§ãïŒMin et al. 2015ïŒã
å šãŠã®èã¿ã€ãã«å®å šã«äœ¿çšã§ãããšããæå€§ã®ã¡ãªãã
ãèãæ¿ããã ãããã¬ãŒã¶ãŒã¯åããŠããªããââããæã蟌ãã§ããæ¹ãžãããã¯æå ±ã§ãã
IPLãã¬ãŒã¶ãŒæ²»çã®å€§ããªèª²é¡ã¯ãèã®è²ãæ¿ãæ£è ïŒã¹ãã³ã¿ã€ãIVãVIïŒã«ãããŠççåŸè²çŽ æ²çïŒPIHïŒã®ãªã¹ã¯ãé«ãããšã§ãããããããMNRFã®æå€§ã®å©ç¹ã®äžã€ã¯ãå ãè²çŽ ïŒã¯ãã¢ãã©ã¢ïŒã«äŸåããªãé«åšæ³¢ãšãã«ã®ãŒã䜿çšãããããèã®è²ã«é¢ä¿ãªãããã¹ãŠã®ã¹ãã³ã¿ã€ãã«ãããŠå®å šæ§ãé«ãããšããããšã§ãïŒIranmanesh et al. 2021ïŒãããã«ããããããŸã§ã¬ãŒã¶ãŒæ²»çãæãããŠããæ¹ããPIHã«æ©ãŸãããŠããæ¹ã§ããå®å¿ããŠèµ€ãé¡ãè質æ¹åã®æ²»çãåããããšãå¯èœã«ãªããŸããã
ãããŸã§3ã€ã®æ²»çæ³ãèŠãŠããŸãããæ¬¡ã«æ°ã«ãªãã®ã¯ãå®éã©ããããå¯äœçšãããã®ãããšããçŸå®çãªåãã§ããå ·äœçãªæ°åã§ç¢ºèªããŸãããã
åæ²»çæ³ã®ãªã¢ã«ãªå¯äœçšçºççãšããŠã³ã¿ã€ã ã®æ¯èŒ
MNRFæ²»çã®ããŠã³ã¿ã€ã ãšå¯äœçšã®è©³çŽ°ãªæ°å€
ãéãåºããŠé»æµãæµããââãã®èª¬æã ãèãã°ã誰ã§ãæããšæããã§ããããã§ããããŒã¿ãèŠãã°è©±ã¯å€ãããŸãã
540åã®æ£è ãå«ã21ã®ç ç©¶ã察象ãšããã·ã¹ãããã£ãã¯ã¬ãã¥ãŒããã³ã¡ã¿ã¢ããªã·ã¹ïŒFoppiani et al. 2025ïŒã«ãããšããã€ã¯ãããŒããªã³ã°æ²»çã¯é¡ã®è¥è¿ãã«ãããŠéåžžã«å®å šãªéžæè¢ã§ããããšã蚌æãããŠããŸããå ±åãããå¯äœçšã®ãã¡æãäžè¬çãªãã®ã¯ãäžéæ§ã®çŽ æïŒäžæçãªèµ€ã¿ïŒãã§ããããã®çºççã¯ããã6.77%ã§ããïŒFoppiani et al. 2025ïŒã
ä»ã®å¯äœçšã¯ããã«äœãæ°åã䞊ã³ãŸããç¹ç¶åºè¡ããã³æµ®è «ïŒè «ãïŒã¯2.07%ãã¹ã±ãŒãªã³ã°ïŒèã®ç®ããïŒã¯1.65%ãçŒç±æã¯1.5%ã也ç¥èã¯0.55%ãäžæçãªè²çŽ æ²çãé·åŒãéè·¡ã¯ããã0.5%ãããççïŒããã¿ïŒã¯0.41%ãšå ±åãããŠããŸãïŒFoppiani et al. 2025ïŒããŸããå¥ã®ã·ã¹ãããã£ãã¯ã¬ãã¥ãŒïŒSitohang et al. 2021ïŒã§ãã9ã€ã®ã©ã³ãã 忝èŒè©ŠéšïŒåèš341人ã®åå è ïŒãåæããçµæããã€ã¯ãããŒããªã³ã°ã¯ã±ãã«ã«ããŒãªã³ã°ãã¢ãã¬ã€ãã£ãã¬ãŒã¶ãŒæ²»çãšæ¯èŒããŠæããã«ããŠã³ã¿ã€ã ãçããé節ãªå¯äœçšã¯äžåå ±åãããŠããªãããšã確èªãããŠããŸãïŒSitohang et al. 2021ïŒã
çã¿ãšèµ€ã¿ã®æç¶æéïŒãªã¢ã«ãªæ£è äœéš
ãæ°åã¯ããã£ããã§ãå®éã©ã®ãããçãã®ïŒãââãã®çåã«ããããŒã¿ãçããŠããŸãã
åè¿°ã®Choãã®ç ç©¶ïŒ2012幎ïŒã§ã¯ãFRMæ²»çäžã®çã¿ã«ã€ããŠãæ£è ã®60%ãã軜床ãã20%ããçã¿ãªãããšåçããŠãããåèš80%ã®æ£è ãæ²»çäžã®çã¿ã蚱容ç¯å²å ãšããŠããŸããäžæ¹ã§ãäžç床ãã13.3%ããé床ãã6.7%ã§ããïŒCho et al. 2012ïŒãçã¿ãæ²»çåŸ3æ¥ä»¥äžç¶ããæ£è ã¯16.7%ã«ãšã©ãŸããŸããããŸããæ²»çã«ããç®ã«èŠããçŽ æïŒèµ€ã¿ïŒã®å¹³åæç¶æéã¯7.8 ± 2.6æ¥ã§ãããããããã¯ãã¹ãŠèªç¶ã«å埩ããåŸéºçãæ®ãããšã¯ãããŸããã§ããïŒCho et al. 2012ïŒã
ããã«å¯ŸããŠãIPLãPDLãªã©ã®å ã»ã¬ãŒã¶ãŒæ²»çã§ã¯ãèšå®ã誀ããšæ°Žç±ïŒæ°Žã¶ããïŒãè²çŽ è±å€±ïŒçœæïŒãé·åŒãççåŸè²çŽ æ²çïŒPIHïŒãªã©ã®ãªã¹ã¯ã䌎ããŸããç¹ã«èæãªã©ã®ä»ã®è²çŽ ç°åžžãæ··åšããŠããå Žåãã¬ãŒã¶ãŒã®ç±ã«ãã£ãŠçç¶ããªããŠã³ãããŠæªåããã±ãŒã¹ãå ±åãããŠããŸãïŒIranmanesh et al. 2021ïŒããããã£ãŠãããŠã³ã¿ã€ã ãæå°éã«æãã€ã€ãå¯äœçšã®ãªã¹ã¯ãåé¿ãããæ£è ã«ãšã£ãŠã¯ãMNRFïŒããã³ãã¡çïŒã極ããŠåªç§ãªéžæè¢ãšãªãããšãããŒã¿ãããè£ä»ããããŠããŸãã
æ£è ã®æºè¶³åºŠãšQOLïŒç掻ã®è³ªïŒã®åäž
客芳çããŒã¿ãšäž»èŠ³çæºè¶³åºŠã®é«ãäžèŽ
æçµçã«ãæãéèŠãªæ°åã¯ããã§ããæ²»çåŸ12é±éã§ã86.7%ã®æ£è ããæºè¶³ããŸãã¯ãéåžžã«æºè¶³ããšåçã
æ²»çã®æåã¯ãå»åž«ããèŠã客芳çãªæ¹åã ãã§ãªããæ£è èªèº«ãé¡ãèŠããšãã«ã©ãã ãæºè¶³ã§ãããïŒPROMsïŒPatient-Reported OutcomesïŒã«ããã£ãŠããŸãïŒFoppiani et al. 2025ïŒãFRMæ²»çãã12é±éåŸã®æ£è æºè¶³åºŠã調æ»ããçµæã§ã¯ããªããš40%ã®æ£è ããéåžžã«æºè¶³ãã46.7%ã®æ£è ããæºè¶³ããšåçããŠãããåèš86.7%ãã®æ£è ãé«ãæºè¶³æãåŸãŠããŸããäžæ¹ã§ãäžæºããšçããã®ã¯ããã3.3%ããéåžžã«äžæºãã¯0%ã§ããïŒCho et al. 2012ïŒã
è峿·±ãããšã«ããã®ç ç©¶ã§ã¯ç®èã®ããªã¢æ©èœã枬ãçµç®æ°Žåèžæ£éïŒTEWLïŒãç®èéïŒsebum measurementsïŒã«ã¯çµ±èšçã«ææãªå€åãèŠãããªãã£ããã®ã®ãç®è衚é¢ã®ç²ãïŒskin surface roughnessïŒã¯æ²»çåŸ2ã4é±éã§äžæçã«ãããã«ç²ããªã£ãåŸã8é±éåŸã«ã¯æããã«æ»ããã«æ¹åããŸããïŒCho et al. 2012ïŒããŸããè¶ é³æ³¢ã§æž¬å®ããçç®å¯åºŠïŒdermal densityïŒã8é±éåŸã«ææãªå¢å ã瀺ããŠãããç®èã®å¥¥æ·±ãããæ§é ãçãŸãå€ãã£ãŠããããšã客芳çã«ã蚌æãããŠããŸãïŒCho et al. 2012ïŒããããã®çç®ã¬ãã«ã§ã®ã³ã©ãŒã²ã³ãšãšã©ã¹ãã³ã®åæ§ç¯ããé¡ã®èµ€ã¿ã®è»œæžã ãã§ãªããæ¯ç©Žã®åŒãç· ããèã®ããªæåäžã«çŽçµããé«ãæ£è æºè¶³åºŠãçã¿åºããŠããã®ã§ãã
ãã®èšäºã®ãŸãšã
- IPLïŒå æ²»çïŒïŒå¹ åºãæ³¢é·ïŒ500ã1200 nmïŒã§èã®ããŒã³å šäœãåäžã«ããã®ã«é©ããŠããŸãããè²çœã®èïŒã¹ãã³ã¿ã€ãIãIIIïŒåãã§ããã匷åãªè¡ç®¡æ¡åŒµã«å¯Ÿããåç¬ã§ã®å¹æã¯ãã€ã«ãã§ãã
- VããŒã ïŒPDLïŒïŒ595 nmã®æ³¢é·ã§æ¡åŒµããè¡ç®¡ããã€ã¬ã¯ãã«ç±ç Žå£ãããèµ€ã顿²»çã®åŒ·åãªæŠåšã§ãããã ããå åºè¡ïŒçŽ«æïŒãè²çŽ æ²çïŒPIHçºçç5.85%ïŒã®ããŠã³ã¿ã€ã ã蚱容ããå¿ èŠããããŸãã
- ããã³ãã¡ïŒMNRFïŒïŒéãšé«åšæ³¢ã®çµã¿åããã«ããã衚ç®ãžã®ãã¡ãŒãžãæå°éã«æããªããçç®ã®è¡ç®¡æ¡åŒµãè¡ç®¡æ°çãæå¶ããŸãããã¹ãŠã®èã¿ã€ãã«å®å šã§ããããè·¡ïŒæ¹åç73.3%ïŒãæ¯ç©ŽïŒé¢ç©58.7%æžå°ïŒãåæã«æ¹åã§ããäžèœåã®ææ°æ²»çã§ããå¯äœçšãäžæçãªèµ€ã¿ãäžå¿ïŒçºçç6.77%ïŒã§å®å šæ§ãéåžžã«é«ãããšãã¡ã¿ã¢ããªã·ã¹ã§å®èšŒãããŠããŸãã
é¡ã®èµ€ã¿ãè¡ç®¡æ¡åŒµã¯ãäžäººã²ãšãã®è質ãåå ã«ãã£ãŠæé©ãªã¢ãããŒããç°ãªããŸãã
ä»åã玹ä»ããèšåºããŒã¿ãå¯äœçšã®æ°å€ãåèã«ããèªèº«ã®ã©ã€ãã¹ã¿ã€ã«ïŒèš±å®¹ã§ããããŠã³ã¿ã€ã ïŒãèã®æ©ã¿ã®æ·±ãã«åãããŠãä¿¡é Œã§ããå°éå»ãšãã£ãããšçžè«ããªãããããªãã«ãšã£ãŠãã¹ããªã¬ãŒã¶ãŒã»ããã€ã¹æ²»çãéžãã§ãã ããã
ãç§ã®å Žåã¯ã©ãã ããïŒããšæã£ãã
ç¡æã«ãŠã³ã»ãªã³ã°ãäºçŽãã
ç¡çãªå§èªã¯ããããŸããããæ°è»œã«ã©ããã
ãã®èšäºãæžãã人
äžæ å®å éåº§é¢ å»åž«
Zetith Beauty Clinic é座é¢ã»å€§éªå¿ææ©é¢ã»çŠå²¡é¢
æ¥æ¬åœå ããã³åœéåŠäŒã§ã®ç ç©¶çºè¡šå®çžŸãæã¡ãZetith Beauty Clinicå šäœã®æè¡æå°ã»æè²ã«ãæºãããè§£ååŠçæ ¹æ ã«åºã¥ãã粟å¯ãªçŸå®¹å»çãå°éãšããäžäººã²ãšãã®éªšæ Œãçµç¹ã«åãããèªç¶ãªä»äžããã远æ±ããŠããã